Literature DB >> 33219752

Hypoxic bone marrow mesenchymal cell-extracellular vesicles containing miR-328-3p promote lung cancer progression via the NF2-mediated Hippo axis.

Xi Liu1, Feng Jiang1, Zhilinag Wang2, Lang Tang1, Bin Zou1, Pengfei Xu1, Tenghua Yu3.   

Abstract

Lung cancer is the most aggressive tumour afflicting patients on a global scale. Extracellular vesicle (EV)-delivered microRNAs (miRs) have been reported to play critical roles in cancer development. The current study aimed to investigate the role of hypoxic bone marrow mesenchymal cell (BMSC)-derived EVs containing miR-328-3p in lung cancer. miR-328-3p expression was determined in a set of lung cancer tissues by RT-qPCR. BMSCs were infected with lentivirus-mediated miR-328-3p knock-down and then cultured in normoxic or hypoxic conditions, followed by isolation of EVs. Following ectopic expression and depletion experiments in lung cancer cells, the biological functions of miR-328-3p were analysed using CCK-8 assay, flow cytometry and Transwell assay. Xenograft in nude mice was performed to test the in vivo effects of miR-328-3p delivered by hypoxic BMSC-derived EVs on tumour growth of lung cancer. Finally, the expression of circulating miR-328-3p was detected in the serum of lung cancer patients. miR-328-3p was highly expressed in EVs derived from hypoxic BMSCs. miR-328-3p was delivered to lung cancer cells by hypoxic BMSC-derived EVs, thereby promoting lung cancer cell proliferation, invasion, migration and epithelial-mesenchymal transition. miR-328-3p targeted NF2 to inactivate the Hippo pathway. Moreover, EV-delivered miR-328-3p increased tumour growth in vivo. Additionally, circulating miR-328-3p was bioactive in the serum of lung cancer patients. Taken together, our results demonstrated that hypoxic BMSC-derived EVs could deliver miR-328-3p to lung cancer cells and that miR-328-3p targets the NF2 gene, thereby inhibiting the Hippo pathway to ultimately promote the occurrence and progression of lung cancer.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  NF2; bone marrow mesenchymal cells; extracellular vesicles; hippo pathway; hypoxic; lung cancer; microRNA-328-3p

Mesh:

Substances:

Year:  2020        PMID: 33219752      PMCID: PMC7810954          DOI: 10.1111/jcmm.15865

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  42 in total

1.  Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1.

Authors:  Y-L Hsu; J-Y Hung; W-A Chang; Y-S Lin; Y-C Pan; P-H Tsai; C-Y Wu; P-L Kuo
Journal:  Oncogene       Date:  2017-04-24       Impact factor: 9.867

2.  Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype.

Authors:  Ling Li; Chao Li; Shaoxin Wang; Zhaohui Wang; Jian Jiang; Wei Wang; Xiaoxia Li; Jin Chen; Kun Liu; Chunhua Li; Guiquan Zhu
Journal:  Cancer Res       Date:  2016-03-18       Impact factor: 12.701

Review 3.  The changing epidemic of lung cancer and occupational and environmental risk factors.

Authors:  Carolyn Dresler
Journal:  Thorac Surg Clin       Date:  2013-02-15       Impact factor: 1.750

Review 4.  The Hippo pathway and human cancer.

Authors:  Kieran F Harvey; Xiaomeng Zhang; David M Thomas
Journal:  Nat Rev Cancer       Date:  2013-03-07       Impact factor: 60.716

5.  Rab11a promotes proliferation and invasion through regulation of YAP in non-small cell lung cancer.

Authors:  Qianze Dong; Lin Fu; Yue Zhao; Yaming Du; Qingchang Li; Xueshan Qiu; Enhua Wang
Journal:  Oncotarget       Date:  2017-04-25

Review 6.  PPAR Agonists for the Prevention and Treatment of Lung Cancer.

Authors:  Sowmya P Lakshmi; Aravind T Reddy; Asoka Banno; Raju C Reddy
Journal:  PPAR Res       Date:  2017-02-20       Impact factor: 4.964

Review 7.  Interventional Analgesic Management of Lung Cancer Pain.

Authors:  Uri Hochberg; Maria Francisca Elgueta; Jordi Perez
Journal:  Front Oncol       Date:  2017-02-14       Impact factor: 6.244

8.  miR-664a-3p functions as an oncogene by targeting Hippo pathway in the development of gastric cancer.

Authors:  Lu Wang; Bowen Li; Lu Zhang; Qing Li; Zhongyuan He; Xuan Zhang; Xiaoxu Huang; Zhipeng Xu; Yiwen Xia; Qiang Zhang; Qiang Li; Jianghao Xu; Guangli Sun; Zekuan Xu
Journal:  Cell Prolif       Date:  2019-03-18       Impact factor: 6.831

9.  MicroRNA‑92a promotes cell proliferation, migration and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells.

Authors:  Krizelle Mae M Alcantara; Reynaldo L Garcia
Journal:  Oncol Rep       Date:  2019-02-19       Impact factor: 3.906

10.  The coiled-coil domain of oncogene RASSF 7 inhibits hippo signaling and promotes non-small cell lung cancer.

Authors:  Xiaoying Zheng; Qianze Dong; Xiupeng Zhang; Qiang Han; Xu Han; Yong Han; Jingjing Wu; Xuezhu Rong; Enhua Wang
Journal:  Oncotarget       Date:  2017-08-12
View more
  9 in total

1.  Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.

Authors:  Shengshu Li; Xiaoxin Lu; Dongyang Zheng; Weizong Chen; Yuzhu Li; Fang Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-30       Impact factor: 4.322

2.  MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44.

Authors:  Zining Qi; Jing Wang; Yaoping Li; Yanzhao Xu
Journal:  J Immunol Res       Date:  2022-05-28       Impact factor: 4.493

3.  Integrative Analysis of Pyroptosis-Related Prognostic Signature and Immunological Infiltration in Lung Squamous Cell Carcinoma.

Authors:  Pengfei Luo; Yongjun Jiang; Sijuan Ding; Shaohui Jiang; Ruoting Tang; Zhaohui Tang
Journal:  Biomed Res Int       Date:  2022-06-01       Impact factor: 3.246

4.  Corrigendum.

Authors: 
Journal:  J Cell Mol Med       Date:  2022-04       Impact factor: 5.310

Review 5.  Emerging roles of extracellular vesicle-associated non-coding RNAs in hypoxia: Insights from cancer, myocardial infarction and ischemic stroke.

Authors:  Dirk M Hermann; Wenqiang Xin; Mathias Bähr; Bernd Giebel; Thorsten R Doeppner
Journal:  Theranostics       Date:  2022-07-18       Impact factor: 11.600

Review 6.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26

Review 7.  MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.

Authors:  Na-Hyun Lee; So Jung Kim; Jeongeun Hyun
Journal:  Biomedicines       Date:  2021-03-30

8.  Hypoxic bone marrow mesenchymal cell-extracellular vesicles containing miR-328-3p promote lung cancer progression via the NF2-mediated Hippo axis.

Authors:  Xi Liu; Feng Jiang; Zhilinag Wang; Lang Tang; Bin Zou; Pengfei Xu; Tenghua Yu
Journal:  J Cell Mol Med       Date:  2020-11-21       Impact factor: 5.310

9.  Tempol Alters Urinary Extracellular Vesicle Lipid Content and Release While Reducing Blood Pressure during the Development of Salt-Sensitive Hypertension.

Authors:  Kevin M Chacko; Mohammad-Zaman Nouri; Whitney C Schramm; Zeeshan Malik; Lauren P Liu; Nancy D Denslow; Abdel A Alli
Journal:  Biomolecules       Date:  2021-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.